These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 18376265

  • 21. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K.
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [Abstract] [Full Text] [Related]

  • 22. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL.
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [Abstract] [Full Text] [Related]

  • 23. Practical grading system for evaluating cisplatin ototoxicity in children.
    Chang KW, Chinosornvatana N.
    J Clin Oncol; 2010 Apr 01; 28(10):1788-95. PubMed ID: 20194861
    [Abstract] [Full Text] [Related]

  • 24. Audiological Monitoring in Children Treated with Platinum Chemotherapy.
    Fetoni AR, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G, Paludetti G.
    Audiol Neurootol; 2016 Apr 01; 21(4):203-211. PubMed ID: 27286730
    [Abstract] [Full Text] [Related]

  • 25. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate.
    Neuwelt EA, Brummett RE, Doolittle ND, Muldoon LL, Kroll RA, Pagel MA, Dojan R, Church V, Remsen LG, Bubalo JS.
    J Pharmacol Exp Ther; 1998 Jul 01; 286(1):77-84. PubMed ID: 9655844
    [Abstract] [Full Text] [Related]

  • 26. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
    Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM.
    Cancer Epidemiol; 2022 Aug 01; 79():102203. PubMed ID: 35724557
    [Abstract] [Full Text] [Related]

  • 27. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
    Dhooge I, Dhooge C, Geukens S, De Clerck B, De Vel E, Vinck BM.
    Int J Audiol; 2006 Jun 01; 45(6):337-43. PubMed ID: 16777780
    [Abstract] [Full Text] [Related]

  • 28. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD.
    Eur J Cancer; 2009 Dec 01; 45(18):3213-9. PubMed ID: 19850470
    [Abstract] [Full Text] [Related]

  • 29. Ototoxicity in children treated for osteosarcoma.
    Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE.
    Pediatr Blood Cancer; 2009 Mar 01; 52(3):387-91. PubMed ID: 19061216
    [Abstract] [Full Text] [Related]

  • 30. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
    Knight KR, Kraemer DF, Winter C, Neuwelt EA.
    J Clin Oncol; 2007 Apr 01; 25(10):1190-5. PubMed ID: 17401008
    [Abstract] [Full Text] [Related]

  • 31. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.
    Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S.
    J Clin Oncol; 2014 Feb 20; 32(6):527-34. PubMed ID: 24419114
    [Abstract] [Full Text] [Related]

  • 32. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
    Biró K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.
    Magy Onkol; 2006 Feb 20; 50(4):329-35. PubMed ID: 17216007
    [Abstract] [Full Text] [Related]

  • 33. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.
    Ear Hear; 2008 Dec 20; 29(6):875-93. PubMed ID: 18753950
    [Abstract] [Full Text] [Related]

  • 34. [Hearing loss caused by high dose carboplatin therapy].
    Lautermann J, Adamczyk M, ten Cate WJ, Kloke O.
    Laryngorhinootologie; 1998 Feb 20; 77(2):82-4. PubMed ID: 9555700
    [Abstract] [Full Text] [Related]

  • 35. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children.
    Macdonald MR, Harrison RV, Wake M, Bliss B, Macdonald RE.
    J Otolaryngol; 1994 Jun 20; 23(3):151-9. PubMed ID: 8064951
    [Abstract] [Full Text] [Related]

  • 36. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.
    Clemens E, de Vries AC, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, Pluijm SF, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ, Neggers SJ, van Grotel M, M van den Heuvel-Eibrink M.
    Pediatr Hematol Oncol; 2017 Mar 20; 34(2):120-129. PubMed ID: 28590156
    [Abstract] [Full Text] [Related]

  • 37. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, Deuster D, Seifert E, Würthwein G, Jaehde U, Pieck AC, Boos J.
    Pediatr Blood Cancer; 2006 Aug 20; 47(2):183-93. PubMed ID: 16302218
    [Abstract] [Full Text] [Related]

  • 38. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma.
    Musial-Bright L, Fengler R, Henze G, Hernáiz Driever P.
    Childs Nerv Syst; 2011 Mar 20; 27(3):407-13. PubMed ID: 20931205
    [Abstract] [Full Text] [Related]

  • 39. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
    Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J.
    Pediatr Blood Cancer; 2012 Jul 15; 59(1):144-8. PubMed ID: 22431292
    [Abstract] [Full Text] [Related]

  • 40. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.
    Clemens E, Brooks B, de Vries ACH, van Grotel M, van den Heuvel-Eibrink MM, Carleton B.
    PLoS One; 2019 Jul 15; 14(2):e0210646. PubMed ID: 30763334
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.